PMID- 23344852
OWN - NLM
STAT- MEDLINE
DCOM- 20130912
LR  - 20211021
IS  - 1573-6903 (Electronic)
IS  - 0364-3190 (Linking)
VI  - 38
IP  - 4
DP  - 2013 Apr
TI  - Intrathecal epigallocatechin gallate treatment improves functional recovery after 
      spinal cord injury by upregulating the expression of BDNF and GDNF.
PG  - 772-9
LID - 10.1007/s11064-013-0976-5 [doi]
AB  - This study aimed to investigate the therapeutic effects of 
      epigallocatechin-3-gallate (EGCG) administered by subarachnoid injection 
      following spinal cord injury (SCI) in rats and to explore the underlying 
      mechanism. Sprague-Dawley rats were randomly divided into four groups of 12 as 
      follows: a sham group (laminectomy only); a control group; a 10 mg/kg 
      EGCG-treated group; and a 20 mg/kg EGCG-treated group. SCI was induced in the 
      rats using the modified weight-drop method (10 g x 4 cm) at the T10 (10th 
      thoracic vertebral) level. EGCG (10 or 20 mg/kg) or vehicle as control was 
      administered by subarachnoid injection at lumbar level 4 immediately after SCI. 
      Locomotor functional recovery was assessed during the four weeks post-operation 
      using open-field locomotor tests and inclined-plane tests. At the end of the 
      study, the segments of spinal cord encompassing the injury site were removed for 
      histopathological analysis. Immunohistochemical and Western blot analyses were 
      performed to observe the expression of: the B cell CLL/lymphoma-2 (Bcl-2), 
      Bcl-2-associated X protein (Bax), brain-derived neurotrophic factor (BDNF) and 
      glial cell line-derived neurotrophic factor (GDNF). The results showed that the 
      EGCG-treated animals had significantly better recovery of locomotor function, 
      less myelin loss, greater Bcl-2 expression and attenuated Bax expression. In 
      addition, the EGCG treatment significantly increased the expression of BDNF and 
      GDNF after SCI. These findings suggest that EGCG treatment can significantly 
      improve locomotor recovery, and this neuroprotective effect may be related to the 
      up-regulation of BDNF and GDNF, and the inhibition of apoptosis-related proteins. 
      Therefore, EGCG may be a promising therapeutic agent for SCI.
FAU - Tian, Wei
AU  - Tian W
AD  - Department of Spine Surgery, Beijing Jishuitan Hospital, No 31, Xinjiekou East 
      Street, Xicheng District, Beijing, People's Republic of China. jstspine@126.com
FAU - Han, Xiao-Guang
AU  - Han XG
FAU - Liu, Ya-Jun
AU  - Liu YJ
FAU - Tang, Guo-Qing
AU  - Tang GQ
FAU - Liu, Bo
AU  - Liu B
FAU - Wang, Yong-Qing
AU  - Wang YQ
FAU - Xiao, Bin
AU  - Xiao B
FAU - Xu, Yun-Feng
AU  - Xu YF
LA  - eng
PT  - Journal Article
DEP - 20130124
PL  - United States
TA  - Neurochem Res
JT  - Neurochemical research
JID - 7613461
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Glial Cell Line-Derived Neurotrophic Factor)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (bcl-2-Associated X Protein)
RN  - 8R1V1STN48 (Catechin)
RN  - BQM438CTEL (epigallocatechin gallate)
SB  - IM
EIN - Neurochem Res. 2020 Jul;45(7):1729-1730. PMID: 32323106
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Brain-Derived Neurotrophic Factor/*biosynthesis
MH  - Catechin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Female
MH  - Glial Cell Line-Derived Neurotrophic Factor/*biosynthesis
MH  - Motor Activity/drug effects
MH  - Neuroprotective Agents/*pharmacology
MH  - Proto-Oncogene Proteins c-bcl-2/biosynthesis
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Recovery of Function/drug effects
MH  - Spinal Cord/drug effects
MH  - Spinal Cord Injuries/*drug therapy/*physiopathology
MH  - bcl-2-Associated X Protein/biosynthesis
EDAT- 2013/01/25 06:00
MHDA- 2013/09/13 06:00
CRDT- 2013/01/25 06:00
PHST- 2012/09/26 00:00 [received]
PHST- 2013/01/17 00:00 [accepted]
PHST- 2013/01/14 00:00 [revised]
PHST- 2013/01/25 06:00 [entrez]
PHST- 2013/01/25 06:00 [pubmed]
PHST- 2013/09/13 06:00 [medline]
AID - 10.1007/s11064-013-0976-5 [doi]
PST - ppublish
SO  - Neurochem Res. 2013 Apr;38(4):772-9. doi: 10.1007/s11064-013-0976-5. Epub 2013 
      Jan 24.